Funding profile · Geroscience therapeutics

Gerostate Alpha

A Buck Institute spinout that raised a small seed round, then took two Regulation Crowdfunding offerings to the public in 2021. The filings run from July 2021 to April 2022 and then stop.

$2.1MSeed round before the crowdfunding, company-reported, at a $15M cap
$849KReported closes of the two 2021 Wefunder offerings combined
$712.5KCash and equivalents at Dec 31, 2021, per the last annual report
1Employees reported in every Regulation Crowdfunding filing

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Summer 2018 Y Combinator, Summer 2018 batch $1,000,000 stated by the founder; YC’s published deal for that period was $120,000 for 7% Y Combinator Claim differs
To early 2021 Seed, at a $15M valuation cap $2,100,000 Not named in any filing Company-stated
Apr to Aug 2021 Reg CF offering 1, SAFE, $15M cap $50,000 target, $1,070,000 maximum; $270,866 final per Form C-U More than 300 individuals, per the CEO Form C and C-U
Jul 2021 Lead investor joins the crowd round Not disclosed; total in the company said to exceed $500,000 at that point Longevitytech.fund, managing partner Petr Sramek Trade press
Oct to Nov 2021 Reg CF offering 2, SAFE, $20M cap $4,500,000 maximum; $572,122 at close Wefunder investors Form C and Kingscrowd
Sep 2026 Wefunder page running total $564,622 465 investors Platform-stated
2018 to 2026 Federal grants None on record NIH RePORTER returns zero awards Not found

What the filings show

Gerostate Alpha Inc. · Form C · filed Jul 20, 2021

Security
Simple Agreement for Future Equity
Offered
$50,000 target · $1,070,000 maximum · deadline Apr 30, 2022
Co-issuers
Gerostate Alpha I and Gerostate Alpha I EB, each a series of Wefunder SPV, LLC, both formed Jul 6, 2021
Intermediary
Wefunder Portal LLC, CRD 283503, paid 3.75% of the offering amount
FY2020 as filed
Assets $415,190 · cash $302,791 · long term debt $2,389,786 · revenue $0 · net loss $636,728
Employees
1
Filing
SEC EDGAR, CIK 0001858392

Gerostate Alpha Incorporated · Form C-U · filed Oct 5, 2021

Progress update
“The final number is $270,866.00 in investments.”
Against
$50,000 target and $1,070,000 maximum
Filing
SEC EDGAR, file number 020-28419

Gerostate Alpha Incorporated · Form C · filed Oct 5, 2021

Offered
$50,000 target · $4,500,000 maximum · deadline Apr 30, 2022
FY2020 as restated
Assets $414,210 · cash $302,791 · long term debt $54,800 · revenue $0 · net loss $640,862
FY2019 as restated
Long term debt $0, against $2,084,986 in the July filing; revenue $0, against $6,000
Employees
1

Gerostate Alpha Incorporated · Form C-AR · filed Apr 28, 2022, for the year ended Dec 31, 2021

Assets
$767,986, against $414,210 a year earlier
Cash
$712,508, against $302,791
Debt
Short term $45,353 · long term $0
Revenue
$0 · net loss $332,457 · taxes paid $800
Employees
1
Signed by
Simon Melov (CEO), Gordon J. Lithgow (Fellow), Edward Lanphier (Director), Mark Lucanic (CTO)

Reading the filings

  1. The crowd paid a third more within weeks.The first offering sold SAFEs at a $15 million cap and closed on August 10, 2021. The second, filed October 5, 2021, carried a $20 million cap. That is a 33 percent step up in under two months, with no priced round and no new peer reviewed result in between.
  2. The balance sheet was restated between two filings eleven weeks apart.For fiscal 2020 the July Form C reported $2,389,786 of long term debt; the October Form C reported $54,800. For fiscal 2019 the figure went from $2,084,986 to $0 and reported revenue from $6,000 to $0. The filings do not explain the change. A reclassification of convertible instruments out of debt would produce this shape, but nothing in the record says so.
  3. Burn halved and the arithmetic is checkable.The 2020 net loss of $640,862 works out to about $53,400 a month, which matches the monthly burn Kingscrowd published for that year. The 2021 net loss of $332,457 is about $27,700 a month. Against $712,508 of cash at the end of 2021, that is roughly 26 months of runway at the 2021 rate and about 13 at the 2020 rate.
  4. The totals do not reconcile.Kingscrowd records closes of $277,216 and $572,122, about $849,000 combined. The Form C-U puts the first offering at $270,866. Wefunder’s own page in September 2026 shows $564,622 from 465 investors, an average of about $1,214 each. No amended filing settles the difference.
  5. The reporting stops.A Regulation Crowdfunding issuer owes an annual report each year until it files a Form C-TR to terminate the duty. The last filing under CIK 0001858392 is the April 28, 2022 annual report. There is no Form C-TR, and no filing of any kind since.

Commercial signals

Signal Detail Source type
Revenue $0 in fiscal 2020 and 2021. The July 2021 filing showed $6,000 for 2019; the October filing restated it to $0. Public record
Regulatory No FDA record, no IND, no registered trial. Aging is not an FDA indication. Public record
Intellectual property No patent or application assigned to Gerostate Alpha. The founders’ patents in this area are assigned to the Buck Institute. Public record
Published evidence One PubMed paper carries the company as an affiliation: a 2021 JBMR Plus mouse study reporting 31% bone volume spared by benzoxazole and no survival benefit. Public record
Status Y Combinator lists the company as Inactive, team size 6. On September 23, 2026 gerostatealpha.com served an unrelated gambling site. Public record

What to watch

  • Any filing under CIK 0001858392, in particular a Form C-AR for a year after 2021 or a Form C-TR.
  • Whether the SAFEs sold in 2021 have a conversion event, and on what terms, given there has been no priced round on record.
  • Whether the Buck Institute licenses the screening hits to anyone else.
  • Any statement to the 465 Wefunder holders about the outcome of their investment.

The Gerostate Alpha story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • GEn1E Lifesciences: Also in Therapeutics. A Palo Alto company built on a different way to hit p38 alpha kinase, a target big pharma abandoned twenty years ago
  • Dorian Therapeutics: Also in Therapeutics. A Stanford spinout that built small molecule blockers of USP16, the enzyme that strips a silencing mark off histone H2A, and pointed them at the arthritic knee
  • Rejuvenation Technologies: Also in Therapeutics. A Stanford spinout that switches telomerase on for a day or two with modified mRNA, then lets it fade
  • Entelexo Biotherapeutics: Also in Therapeutics. An Irvine company engineering exosomes into drug candidates for autoimmune disease, built on published UC Irvine research

Sources

  1. Public recordForms C and C-U, CIK 0001858392SEC EDGAR · Jul and Oct 2021
  2. Public recordForm C-AR for the year ended Dec 31, 2021SEC EDGAR · Apr 28, 2022
  3. Public recordThe Y Combinator Deal, archived page stating $120k for 7%Y Combinator via Internet Archive · Aug 2018
  4. Public recordGoogle Patents searches for Gerostate Alpha and its foundersGoogle Patents · accessed Sep 23, 2026
  5. Public recordNIH RePORTER and ClinicalTrials.gov searches for Gerostate, zero results in eachNIH and NLM · accessed Sep 23, 2026
  6. IndependentGerostate Alpha on Wefunder 2021, valuations, closes and burnKingscrowd, Sweeny Kumar · Oct 2021
  7. IndependentTwo reports on the crowdfunded raiseLongevity.Technology · Apr and Jul 2021
  8. IndependentLongevity Marketcap Telemetry #027Nathan Cheng · Apr 13, 2021
  9. Public recordLongitudinal Functional Study of Murine AgingJBMR Plus, Evans and colleagues · Mar 2021
  10. CompanyWefunder company page, totals raised and investor countWefunder · Sep 23, 2026
  11. CompanyCompany page, batch, team size and statusY Combinator directory · Sep 23, 2026

Compiled from SEC, NIH, Google Patents and other public records and published reports as of September 22, 2026. Form C notices report offerings under Regulation Crowdfunding; amounts reflect the filing date and may not capture later sales or cancellations. Healthcare Venture Capital Fund holds no position in Gerostate Alpha. This page is not an offer to sell or a recommendation to buy any security.